Trial Outcomes & Findings for Rates of Middle Meatus Synechiae Formation Post ESS (NCT NCT03036735)

NCT ID: NCT03036735

Last Updated: 2018-10-19

Results Overview

Steroid eluting spacer will be measured by incidence of 35 and 90-day post Functional Endoscopic Sinus Surgery (FESS) incidence of middle meatal synechiae.

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

10 participants

Primary outcome timeframe

35 to 90days

Results posted on

2018-10-19

Participant Flow

Study was terminated prematurely

Participant milestones

Participant milestones
Measure
Drug Eluding Spacer
Restora Mometasone Furate spacer
Overall Study
STARTED
10
Overall Study
COMPLETED
0
Overall Study
NOT COMPLETED
10

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Rates of Middle Meatus Synechiae Formation Post ESS

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Drug Eluding Spacer
n=10 Participants
nasal drug eluding spacer
Age, Categorical
<=18 years
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
7 Participants
n=5 Participants
Age, Categorical
>=65 years
3 Participants
n=5 Participants
Sex: Female, Male
Female
4 Participants
n=5 Participants
Sex: Female, Male
Male
6 Participants
n=5 Participants
Region of Enrollment
United States
10 participants
n=5 Participants

PRIMARY outcome

Timeframe: 35 to 90days

Population: Study was terminated , funds withdrawn. No data was collected or analyzed.

Steroid eluting spacer will be measured by incidence of 35 and 90-day post Functional Endoscopic Sinus Surgery (FESS) incidence of middle meatal synechiae.

Outcome measures

Outcome data not reported

Adverse Events

Steroid Eluting Spacer

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Steroid Eluting Spacer
Subjects will receive one steroid eluting spacer (Restora Mometasone Furate Eluting Spacer) placed into the surgical site on one side, and one spacer without drug (Silastic spacer) placed on the other side. The Restora Mometasone Furate Eluting Spacer will be compared to the Silastic spacer. steroid eluting spacer: The Restora Mometasone Furate Eluting Spacer will be compared to the Silastic spacer.
Ear and labyrinth disorders
Study was terminated for lack of funds
0/0
study was terminated and funds with drawn. No data was obtained.

Other adverse events

Adverse event data not reported

Additional Information

Dr Peter Catalano

Steward Health Care

Phone: 617-789-5004

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place